KIF25

Across TCGA pan-cancer cohorts, KIF25 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KIF25 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KIF25 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF25 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and ACC are the cancer types where KIF25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.229	0.721	<.001	43	view →
UCEC	DFS	Median	II,III,IV	1.000	0.435	.011	30	view →
ACC	OS	Median	All	0.135	0.632	.001	12	view →
COAD	DFS	Median	All	0.153	0.794	<.001	12	view →
LUAD	OS	Median	All	0.211	0.673	.006	6	view →
LIHC	DFS	Median	All	0.174	0.546	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KIF25–LUSC (DFS)

Open the LUSC breakdown →